ClinicalTrials.gg
Not yet recruitingNCT07321418Updated Jan 7, 2026

Mid-term Results of Epiphyseal Transfer for Hip Post Septic Epiphyseal Loss

An observational study in Septic Arthritis of the Native Hip and Epiphyseal Arrest, Lower Leg, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
20
Sex
All
01

Study summary

Absence or loss of the growth plate together with the epiphysis of a long bone presents a very difficult condition to treat. An example of this is the loss of the head and neck of the femur especially as a part of severe sequelae of infantile septic arthritis.

Read the detailed description

Ever since its advent by Taylor in 1975 , the vascularized fibular free flap has gained popularity and became the gold standard to reconstruct challenging bony defects of the head, neck and extremities. Vascularized fibular flaps offer a great deal of versatility, particularly when reconstructing bony defects larger than 6 cm. In skeletally immature patients, vascularized epiphyseal transfer allows for reconstruction of complex bony defects preserving ongoing longitudinal growth, and provides a reliable articular surface for effective joint function. Although the proximal fibular growth plate is the most popular type of transfer. Therefore, it's mandatory to assess follow up of patients underwent epiphyseal transfer.

Earlier reports of proximal fibular epiphyseal transfer described the use of the peroneal vessels as the pedicle, However the results were overall disappointing and the peroneal artery alone was concluded to be insufficient to support the physeal growth plate. A bipedicled transfer, using the peroneal vessels to support the diaphysis and the anterior tibial vessels or the inferior lateral genicular vessels to support the epiphysis was attempted. Although this showed better outcomes, it was technically more demanding and had a higher risk of complications. Taylor reported the use of the anterior tibial vessels as a single pedicle with success after confirming its role in the blood supply of the fibular diaphysis and epiphysis in a cadaveric study. Another study further popularized the use of the anterior tibial pedicle after introducing the "reverse flow" method and describing the harvest technique. A reported drawback for the use of the anterior tibial pedicle was the occasional need to transect branches of the deep peroneal nerve during the harvest due to their complex relation to the vessels.

This variability in the vascular pedicle employed mandated to the need for a detailed anatomical study of the blood supply of the proximal fibula including the head region, and the supplying vessels, in order to give surgeons appropriate information for choosing the ideal vessel for these complex cases and minimize donor site morbidity. To the best of our knowledge, no such study has been conducted or published in the literature. Moreover, no study has described the anatomic relationship of the deep peroneal nerve branches to the tibialis anterior muscle and their relation to the supplying vessels, which represents another obstacle in the face of popularizing this highly beneficial technique.

Absence or loss of the growth plate together with the epiphysis of a long bone presents a very difficult condition to treat. An example of this is the loss of the head and neck of the femur especially as a part of severe sequelae of infantile septic arthritis. Another example is congenital radial longitudinal deficiency with a previously failed centralization procedure. Management strategies of these and similar problematic conditions are limited and unsatisfactory, with major residual functional disability. Vascularized epiphyseal transfer presents a potential solution to such problems.

02

Conditions studied

  • Septic Arthritis of the Native Hip
  • Epiphyseal Arrest, Lower Leg

Browse trials for

Keywords

  • epiphyseal transfer
  • epiphyseal loss
  • post septic hip
03

In context

Arthritis, Infectious

51 studies on the registry are indexed under Arthritis, Infectious; 12 are open to participants now.

This study's planned enrollment of 20 is below the median of 100 across 30 observational studies indexed under Arthritis, Infectious.

Browse Arthritis, Infectious studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  • All cases in Hand and Reconstructive Microsurgery Unit in AUH with epiphyseal transfer for hip post-septic epiphyseal loss.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All cases in Hand and Reconstructive Microsurgery Unit in AUH with epiphyseal transfer for hip post-septic epiphyseal loss.
  • Minimum 5 years Follow-up records .

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled local infection .
  • Patients with incomplete data.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Functional outcome of the hip.

    • Bone union will be evaluated according to de Boer et al in 1989

    Time frame: 5 years

  2. functional outcome

    The Oxford Hip Score (OHS) for hip function

    Time frame: 5 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2028, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2025
First posted
Jan 7, 2026
StartEst.
Dec 25, 2025
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 30, 2028
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07321418
Lead sponsor
Assiut University
Responsible party
Mostafa Ahmed Mostafa Abdelbaky (Resident, Assiut University) — Principal investigator
First posted
Jan 7, 2026
Start date
Dec 25, 2025 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jan 7, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion